The NMI is a member of the Innovation Alliance Baden-Württemberg. It is involved in application-oriented research at the interface between the life sciences and material science. An interdisciplinary team of scientists is developing new technologies for companies and public research sponsors in the areas of Pharma and Biotech, Biomedicine and Materials Science, and Material Analysis and Electron Microscopy.
The Tumor Biology Group at the NMI is engaged in translational oncology projects by applying 3D microtumor models derived from primary tumor tissue for preclinical compound testing as well as for research projects focused on immuno-oncology and functional cell biology. In this context, we are working on the further development of this model system with regard to its integration with microfluidic chip systems.
This position is available to start immediately.
The parallel testing of compounds and their combinations in patient-derived, ex vivo model systems allows a quantification of the clinical efficiency as well as the testing of toxicities in a clinically relevant time frame. In contrast to conventional static culture systems, microfluidic chip platforms integrate spatial organization and guided, mostly adjustable media perfusion and diffusion.
In this thesis, you will work on establishing patient-derived tumor models and combining them with perfused chip systems for long-term analysis of compound effects and tumor-immune cell interactions.
Your contact person
Frau Katja Rösslein